New Technology from Emulsi Biotech Can Make Biological Drugs More Effective

Lund, Sweden – Emulsi Biotech is developing a groundbreaking platform technology for the oral delivery of drugs. Their innovative NanoLIPID platform has the potential to protect drug substances, enable slow release, and significantly enhance the body's absorption of medications. The company has been accepted into SmiLe's incubator program. 

Biological drugs are becoming increasingly common in the treatment of rheumatic diseases, type 2 diabetes, and obesity. One of the main challenges with these expensive drugs is that patients often can only absorb a small fraction of the dose contained in a tablet or capsule. 

Emulsi Biotech's innovation has the potential to radically improve the body's ability to absorb the drug. This could lead to better effectiveness, lower doses, and fewer treatment sessions. It could also result in fewer side effects and lower medication costs. 

The company’s NanoLIPID technology is based on research from Lund University. The method involves combining the active drug with specific oil mixtures, which are then taken orally in capsule form. Once inside the body, these oils form a gel-like protective layer around the drug, with tiny nano-sized channels that allow for slow release. 

This technology can be applied to a wide range of drugs. The primary customers will be pharmaceutical companies developing complex biologic drugs and other treatments where drug absorption is an issue. 

Emulsi Biotech has been accepted into the SmiLe Venture Hub incubator program, giving them access to SmiLe’s experts, network, and extensive resources to accelerate their growth. 

"We are delighted to welcome Emulsi Biotech back to SmiLe. They were one of the participants in our Biotech Bootcamp last year, and their progress since then has been remarkable. With their technology, they address several major challenges related to absorption, distribution, and side effects. We are very happy to welcome the company to SmiLe and to support their development journey," says Ulrika Ringdahl, CEO of SmiLe Venture Hub. 

"We have founded Emulsi Biotech to bridge the gap between cutting-edge research and commercial applications, driven by a vision to make life-saving drugs more accessible and effective. Joining SmiLe Incubator was a strategic decision to leverage its world-class ecosystem of mentors, labs, and industry connections,” says Eimantas Gladkauskas, CEO of Emulsi Biotech. 

 

For more information, please contact: 
Ulrika Ringdahl, CEO of SmiLe Venture Hub AB,    
+46 (0)73 656 6232, ulrika.ringdahl@smileincubator.life 

or 
Eimantas Gladkauskas, CEO of Emulsi Biotech AB, 
+46702529922, eg@emulsibiotech.com